Studies on PIVKA VII.
In 30 subjects on stabilized oral anticoagulant treatment, factor VII activity (VII:C) and factor VII antigen (VII:Ag) were evaluated. The average VII:C and VII:Ag levels were 8.7 and 30.7, respectively. All plasma samples were treated with 1 M barium chloride: all the activity and a corresponding average amount of antigen were adsorbed by the salt. The cold-promoted activation of factor VII was found in 5/30 subjects. Corresponding amounts of VII:C and VII:Ag were also removed from the plasma of these subjects after cold activation following the addition of barium chloride. It clearly results from these studies that a portion of VII:Ag cannot be adsorbed by barium chloride because of a reduction (or a lack) of the gamma-carboxyglutamic groups. This portion of VII:Ag can therefore be identified as Pivka VII.
D000074:Acenocoumarol / Q000627:therapeutic use*; D000941:Antigens / Q000378:metabolism; D015415:Biomarkers; D001777:Blood Coagulation / Q000187:drug effects; D003080:Cold Temperature; D005167:Factor VII / Q000276:immunology / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D011498:Protein Precursors / Q000378:metabolism*; D011516:Prothrombin / Q000378:metabolism*
D000941:Antigens; D015415:Biomarkers; D011498:Protein Precursors; C031500:factor VII related antigen; C008208:acarboxyprothrombin; D005167:Factor VII; D011516:Prothrombin; D000074:Acenocoumarol